The Effect of the New Patent Amendment on Pharmaceutical Companies
INTRODUCTION Whether the Indian pharmaceutical firms are indeed innovating in developing new drugs or just incrementally improving the existing drugs to gain patents and arrive on the drug market. Indian Pharmaceutical Industry: regained focus on research and development, having turned out as the fourth largest in the world in volume terms (8% of global production) […]
Patents in Medicine: Balancing Incentive and Access to Healthcare
Introduction: The development of drugs and other medical products is very important in this dynamic world. Innovation in the healthcare industry has become a pivotal part of everyone’s lives worldwide. Through the invention of various drugs and other medical products, the world has been able to deal with multitudinous life-changing conditions over time. Intellectual Property […]
Biotechnology and Intellectual Property: Balancing Innovation and Access to Genetic Resources
Introduction The field of Biotechnology has been growing tremendously in the past few years, it is a dynamic field at the intersection of biology and technology, encompassing a broad range of applications aimed at improving human life and the environment.1 The UN defines Biotechnology as “any technological application that uses biological systems, living organisms, or […]
Patenting of a Drug Under IPR.
Introduction This particular blog is on the subject matter that how a drug patent can be obtained under the patent law in India and in this context the landmark judgement of the Supreme court- Novartis v. Union of India has been covered in this blog. In this blog the various facets with respect to getting […]
Natco Files India’s First Compulsory Licensing Application
Natco Pharma has filed India’s first Compulsory Licensing (CL) Application (in accordance with Section 84(1) of the Indian Patents Act) against one of the Bayer’s patented drug Sorafenib, marketed by Bayer as Nexavar for treating Kidney and Liver Cancer. Patent on Sorafenib is granted in India on 03.03.2008 having number IN 215758. This will be […]
Inventors – All Technologies Are not Worth Billions
Working in the IP/Technology Commercialization and Out-Licensing domain makes you assess and evaluate the commercial viability of numerous IP backed inventions across technology domains. Apart from learning about and assessing new technologies, we also tend to learn quite a lot about Inventors’ mindset, specifically about their perspective of their own inventions. This article relates to […]
Inventors – All Technologies Are not Worth Billions
Working in the IP/Technology Commercialization and Out-Licensing domain makes you assess and evaluate the commercial viability of numerous IP backed inventions across technology domains. Apart from learning about and assessing new technologies, we also tend to learn quite a lot about Inventors’ mindset, specifically about their perspective of their own inventions. This article relates to […]
Food Market making Profit from Climatic Changes
Climatic changes being a source of making a profit for food crop manufacturers. Adverse changes in climate have triggered the ecosystems affecting crops, livestock, fisheries and forests, and the billions of people whose livelihoods depend on them. Extreme climate events (especially hotter, drier conditions in semi-arid regions) are likely to slash yields for maize, wheat, […]
Indian Pharmaceutical Industry Licensing Deals: Case Studies
Glenmark Pharmaceuticals Glenmark, research-driven, global, integrated pharmaceutical company with Research Focus on Inflammatory Diseases, Metabolic Disorders and Pain has a presence in over 80 countries around the world. The Company has a proven track record of entering into Licensing deals with Big Pharma and entered into Outlicensing deals in 2004 with Forest laboratories for Oglemilast, […]